Therapy Areas: AIDS & HIV
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
3 March 2025 - Rare disease pharmaceutical company QOL Medical LLC reported on Saturday that Sucraid (sacrosidase) Oral Solution has been shown to be 81% effective in the treatment of patients with Co...
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
28 February 2025 - Swedish bioinformatics software provider Qlucore AB (Nasdaq First North Growth Market:QCORE) on Friday introduced the first CE-marked diagnostic test for paediatric leukaemia under ...
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
24 February 2025 - Bruker Corporation (Nasdaq: BRKR), a US-based manufacturer of scientific instruments for molecular and materials research, announced on Monday that it showcased significant advancem...
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
4 February 2025 - French pharmaceutical company Mitem Pharma revealed on Tuesday that it has acquired the rights to Flisint (fumagillin) from Sanofi Winthrop Industrie, part of French healthcare compa...
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
22 January 2025 - Danish hearing care company Audientes A/S announced on Wednesday that it has signed a strategic distribution agreement with Istanbul-based Audivista.This collaboration aims to expand...
Benuvia Operations signs licensing deal with Avernus Pharma
11 December 2024 - Benuvia Operations LLC, a US-based contract development and manufacturing organisation, announced on Tuesday that it has signed a licensing agreement with Avernus Pharma, a Dubai-ba...